SARTORIUS-STEDIM-BIOTECH
Sartorius Stedim Biotech (SSB) (Paris:DIM), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others.
Under agreements signed today, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs.
“We have a long-standing and productive partnership with SSB and we will continue to work together to provide solutions for customers as they bring medicines to patients,” said Marc Funk, COO Lonza Pharma & Biotech. “As new generations of complex biologics move towards commercial production, media is no longer viewed a consumable but a critical part of the package we offer customers developing next-generation therapies, and we are investing accordingly in this area.”
“Our collaboration over the past years has greatly benefited our customers and both companies. The adapted agreement now reflects the dynamics of this rapidly evolving market, providing additional strategic flexibility for both partners,” commented Reinhard Vogt, Member of Sartorius Stedim Biotech’s Executive Committee.
Sartorius Stedim Biotech and Lonza have also entered into a further long-term agreement for supply of equipment and consumables. Under the new agreement, SSB will be a preferred supplier for specific Lonza projects. As Lonza increases its capacity for small-scale manufacturing, notably through the recently announced IbexTM Design and Develop in Visp (Switzerland), strong partnerships are key to offering the best solutions for customers. “We see us well positioned and are very much looking forward to supporting Lonza to implement next-generation manufacturing concepts at their Visp and other sites”, added Vogt.
This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.
Current Image Files
Reinhard Vogt, Member of Sartorius Stedim Biotech’s Executive Committee
https://www.sartorius.com/en/company/newsroom/downloads-publications
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2017, Sartorius Stedim Biotech employed approx. 5,100 people and earned sales revenue of €1,081.0 million. For further information, visit www.sartorius.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005871/en/
Contact:
Petra Kirchhoff Corporate Communications Sartorius Corporate Administration GmbH +49 (0)551.308.1686 petra.kirchhoff@sartorius.com www.sartorius.com Follow us on Twitter: www.twitter.com/Sartorius_Group
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri ArcGIS Location PlatformAdds Session Usage Pricing for Basemaps8.10.2025 20:44:00 CEST | Press release
New Model Offers Predictable, Flexible Cost Structure for High-Traffic and Long-Session Applications Esri, the global leader in location intelligence, today announced the release of a new session usage pricing model for basemaps available through ArcGIS Location Platform. This session usage model complements the existing tile usage pricing, which customers will still have the option to choose based on their operational needs. Developers and organizations will now have a more predictable and cost-effective way to integrate Esri’s high-quality basemaps into their applications and business systems. The additional pricing option for ArcGIS Location Platform is especially valuable for high-traffic applications or those with extended user sessions, such as real estate search portals, rideshare apps, or delivery tracking systems. By aligning pricing with actual user interactions—such as panning, zooming, and searching—developers can better forecast costs. “Organizations struggle with unpredic
Forum Invest in Senegal 2025 (Fii Senegal 2025): President Bassirou Diomaye Faye Calls for Investment in a Transforming Senegal8.10.2025 19:50:00 CEST | Press release
“Senegal offers a growing market within the framework of the Continental Free Trade Area, supported by a legal environment undergoing modernization and reform. We are ready to welcome you and facilitate your establishment and success. Come seize opportunities in high-potential strategic sectors and forge fruitful, mutually beneficial partnerships,” stated His Excellency President Bassirou Diomaye Faye at the opening of Forum Invest in Senegal 2025 (Fii Senegal 2025) (https://FiiSenegal.sn/). With these words, the Head of State set the tone for a forward-looking forum, symbolizing a Senegal firmly committed to the path of economic transformation, stability, and trust. The President reiterated the four pillars of Vision Senegal 2050—economic diversification, regional development, strengthened governance, and investment in human capital—as the guiding framework for the country’s long-term development. Following this, Bakary Séga Bathily, Director General of APIX, welcomed this direction,
Bacardi Legacy of Great Workplace Continues With Forbes Honor of “World’s Best Employers” in 20258.10.2025 17:25:00 CEST | Press release
Family-Owned Company Earns Top Rank Within Spirits Bacardi Limited is proud to once again land a spot on the Forbes’ list of the ‘World’s Best Employers 2025’ — proving that great people and a great culture never go out of style. The family-owned company is a repeat show on the global list which is based on more than 300,000 independent surveys conducted in more than 50 countries. Participants were asked whether they would recommend a company to family or friends, and to rate it based on such criteria as workplace environment, salary, and other key criteria. Bacardi, the world’s largest privately held international spirits company, earned the highest ranking of pure spirits companies coming in at #86. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008919280/en/ Bacardi legacy of great workplace continues. “Being recognized again by Forbes among the World’s Top Employers is a true testament to our culture and the dedicatio
DevvStream Reports BTC and SOL Reserves as Crypto-Treasury Program Accelerates8.10.2025 17:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today reported current holdings and progress under its crypto-treasury program, which is designed to add 24/7 liquidity and generate staking income. Portfolio snapshot (BitGo custody): Bitcoin ($BTC): approximately 22.229 BTC held, valued at (US) $2,716,162 as of October 7, 2025. Solana ($SOL): 12,110.98 SOL acquired year-to-date; 12,127.64 SOL staked, including rewards. Total SOL held is valued at (US) $2,718,489 as of October 7, 2025. USD balance: approximately (US) $1,280,000 in cash within BitGo. The Company has retained all digital-asset holdings accumulated under the program to date. The treasury is intended to create incremental income through SOL staking and establish on-chain readiness for tokenized real-world assets, including renewable-energy plants, energy-trading contracts, and other sustainability
Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product8.10.2025 16:51:00 CEST | Press release
A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes “Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.’” Experts from Philip Morris International Inc. (NYSE: PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). The full-day meeting on October 7 was part of the FDA’s customary review of PMI’s request to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products (MRTPs), a necessary ste
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom